Novartis

Novartis is a global healthcare company headquartered in Basel, Switzerland, formed through the landmark merger of Ciba-Geigy and Sandoz in 1996. It operates across two core segments: Innovative Medicines and Sandoz, the latter focusing on generics and biosimilars. The company is a leader in the development of treatments across multiple therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular disease.

History

The company's origins trace back to the 1996 merger of two Basel-based chemical and life sciences giants, Ciba-Geigy and Sandoz, a deal orchestrated by leaders including Daniel Vasella. This created one of the world's largest pharmaceutical companies at the time. Key early milestones included the launch of blockbuster drugs like Gleevec for chronic myeloid leukemia and the acquisition of Chiron Corporation in 2006 to bolster its vaccine and blood testing divisions. A major strategic shift occurred in 2023 with the successful spin-off of its Sandoz division as a separate publicly traded entity on the SIX Swiss Exchange. Throughout its history, it has engaged in significant transactions, including the multi-billion dollar acquisition of The Medicines Company for its inclisiran asset and the sale of its Roche stake.

Corporate affairs

The company is governed by a Board of Directors chaired by Joerg Reinhardt, with Vas Narasimhan serving as Chief Executive Officer. Its global operations are structured into two commercial units: Innovative Medicines and the now-independent Sandoz. Major research and development facilities are located in Cambridge, Massachusetts, Basel, and Emeryville, California, home to the Novartis Institutes for BioMedical Research. It maintains significant manufacturing sites worldwide and holds a prominent listing on the SIX Swiss Exchange under the ticker symbol NOVN. The organization has undergone several major restructurings, including the integration of AveXis and the Alcon divestiture, to focus on advanced therapy platforms.

Products and research

Its portfolio includes groundbreaking therapies such as Kymriah, a CAR-T cell therapy for certain lymphomas, and Zolgensma, a gene therapy for spinal muscular atrophy. The company has a strong legacy in oncology with drugs like Tasigna and Kisqali, and in cardiovascular disease with Entresto. Its Novartis Institutes for BioMedical Research spearhead discovery in areas like radioligand therapy and RNA technologies. The spun-off Sandoz division remains a global leader in generic pharmaceuticals and biosimilars, marketing copies of complex biologics like Humira. Key recent approvals include iptacopan for paroxysmal nocturnal hemoglobinuria.

Controversies and legal issues

The company has faced numerous legal and ethical challenges, including a high-profile 2020 settlement with the U.S. Department of Justice over alleged violations of the False Claims Act related to speaker programs. It has been subject to investigations by the Securities and Exchange Commission concerning payments to entities associated with Michael Cohen. In Japan, its subsidiary faced allegations over manipulated data for the drug Diovan. It has also been involved in major patent disputes, such as those concerning Gleevec in India, and has paid significant settlements in kickback cases with the U.S. Department of Health and Human Services.

Corporate social responsibility

Through the Novartis Foundation, it runs long-term initiatives to combat leprosy and malaria and improve cardiovascular health in low-income communities. The company's Access to Medicines program provides a portfolio of medicines on a non-profit basis to the world's poorest countries. It is a signatory to the UN Global Compact and sets environmental targets aligned with the Paris Agreement. The Novartis Venture Funds invest in early-stage biotechnology companies, and its Corporate Citizenship efforts include disaster relief partnerships with the International Federation of Red Cross and Red Crescent Societies.

Category:Pharmaceutical companies of Switzerland Category:Companies listed on the SIX Swiss Exchange Category:Companies based in Basel